FDA CDER Bioanalytic Methods Validation Guidance

This guidance for those involved in Drug application (INDs, ANDAs) provides guidance for methods validation. It mentions software platform changes as a possible reason for partial validation:
“Partial validations are modifications of already validated bioanalytical methods. Partial validation can range from as little as one intra-assay accuracy and precision determination to a nearly full validation. Typical bioanalytical method changes that fall into this category include, but are not limited to:
Changes in instruments and/or software platforms”.

The full guidance is at the link provided.

SoftwareCPR keywords: software, drugs, pharmaceuticals, NDA, IND, CDER,

Cybersecurity Review

Our cybersecurity experts are NESSUS Pro Licensed and can quickly remediate cybersecurity deficiencies with your medical device or digital health software.  Planning, requirements, validation, and submissions – we can assist with all.

Interested in having a conversation?  Email us to arrange a Zoom meeting or call us at +1 781-721-2921.

office@softwarecpr.com

Corporate Office

15148 Springview St
Tampa, FL 33624
USA
+1-781-721-2921
Partners located in the US (CA, FL, MA, MN), Canada, and Italy.